News | April 27, 2026
Nihilent unveils nSEPIA Beta to turn emotional wellness into measurable science
nSEPIA aims to bring structure to an area long dominated by subjectivity
nSEPIA aims to bring structure to an area long dominated by subjectivity
The first Phase III and second Phase III trials will be multi-centre, randomised, assessor-blind, active-comparator studies to determine the efficacy, safety and tolerability of orally administered Zintrodiazine
New model focuses on continuity of care, combining therapy, routine and social engagement to support long-term recovery
FTIR and machine learning-based technology enables real-time, cost-effective quantification of food adulterants
Multidisciplinary team expansion brings integrated medical, surgical, and radiation oncology services under one roof
VESCOP, ENTOD Pharmaceuticals, and APTI-MSB host the event to bridge lab-to-clinic gap in eye care
The webinar series will showcase next-gen imaging technologies, global expert insights, and hands-on sessions on microscopy innovations
The agreements aim to strengthen medicine quality, patient safety and pharmaceutical research in India
The summit brought together over 150 doctors, researchers, and practitioners worldwide
Profitability came under strain. Gross profit fell to EUR 246m, with margins narrowing to 23.7% as negative product mix—particularly in Asia Pacific—weighed on performance
Subscribe To Our Newsletter & Stay Updated
